ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis - PubMed (original) (raw)
. 2006 Dec;449(6):628-36.
doi: 10.1007/s00428-006-0315-1. Epub 2006 Nov 8.
Affiliations
- PMID: 17106710
- DOI: 10.1007/s00428-006-0315-1
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis
Florian R Fritzsche et al. Virchows Arch. 2006 Dec.
Abstract
Gene products of the A disintegrin and metalloprotease (ADAM) family are critically involved in carcinogenesis and tumor progression of various solid tumors. Little is known about ADAM8 in prostate cancer. In our quest for novel diagnostic tissue markers of prostate cancer, we aimed to evaluate the expression of ADAM8 in prostate cancer and to correlate it with clinicopathological parameters. One hundred twenty-eight clinicopathologically characterized prostate cancer patients, with available follow-up data, were immunostained for ADAM8. Additionally, ADAM8 mRNA expression was quantified by real-time reverse transcription polymerase chain reaction (n = 59). ADAM8 protein expression was significantly associated with higher pT status, positive nodal status, and higher Gleason scores. Still, a significant prognostic value for the prostate-specific antigen relapse-free survival of ADAM8 could not be demonstrated. The differentiality of ADAM8 expression on protein and on mRNA level was low and partially inconclusive. Therefore, despite of its significant association with conventional parameters of an unfavorable prognosis, ADAM8 adds only limited information to the conventional histopathological assessment of prostate cancer.
Similar articles
- Prognostic and clinical implication of a disintegrin and metalloprotease 8 expression in pediatric medulloblastoma.
Zhang R, Yuan Y, Zuo J, Liu W. Zhang R, et al. J Neurol Sci. 2012 Dec 15;323(1-2):46-51. doi: 10.1016/j.jns.2012.07.040. Epub 2012 Sep 7. J Neurol Sci. 2012. PMID: 22959284 - ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grützmann R, Jung K, Kristiansen G. Fritzsche FR, et al. Eur Urol. 2008 Nov;54(5):1097-106. doi: 10.1016/j.eururo.2007.11.034. Epub 2007 Nov 26. Eur Urol. 2008. PMID: 18061337 - ADAM9 decreases in castration resistant prostate cancer and is a prognostic factor for overall survival.
Lin GW, Yao XD, Ye DW, Zhang SL, Dai B, Zhang HL, Ma CG. Lin GW, et al. Chin Med J (Engl). 2012 Nov;125(21):3800-5. Chin Med J (Engl). 2012. PMID: 23106877 - A jack of all trades - ADAM8 as a signaling hub in inflammation and cancer.
Cook L, Gharzia FG, Bartsch JW, Yildiz D. Cook L, et al. FEBS J. 2024 Sep;291(18):3989-4008. doi: 10.1111/febs.17034. Epub 2023 Dec 22. FEBS J. 2024. PMID: 38097912 Review. - ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies.
Koller G, Schlomann U, Golfi P, Ferdous T, Naus S, Bartsch JW. Koller G, et al. Curr Pharm Des. 2009;15(20):2272-81. doi: 10.2174/138161209788682361. Curr Pharm Des. 2009. PMID: 19601829 Review.
Cited by
- The versatile roles of ADAM8 in cancer cell migration, mechanics, and extracellular matrix remodeling.
Mierke CT. Mierke CT. Front Cell Dev Biol. 2023 Feb 23;11:1130823. doi: 10.3389/fcell.2023.1130823. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36910158 Free PMC article. Review. - Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases.
Pluda S, Mazzocato Y, Angelini A. Pluda S, et al. Front Mol Biosci. 2021 Jul 21;8:703715. doi: 10.3389/fmolb.2021.703715. eCollection 2021. Front Mol Biosci. 2021. PMID: 34368231 Free PMC article. Review. - The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.
Binder MJ, Ward AC. Binder MJ, et al. Int J Mol Sci. 2021 Mar 30;22(7):3608. doi: 10.3390/ijms22073608. Int J Mol Sci. 2021. PMID: 33808504 Free PMC article. - Expression levels of the metalloproteinase ADAM8 critically regulate proliferation, migration and malignant signalling events in hepatoma cells.
Awan T, Babendreyer A, Mahmood Alvi A, Düsterhöft S, Lambertz D, Bartsch JW, Liedtke C, Ludwig A. Awan T, et al. J Cell Mol Med. 2021 Feb;25(4):1982-1999. doi: 10.1111/jcmm.16015. Epub 2020 Dec 13. J Cell Mol Med. 2021. PMID: 33314720 Free PMC article. - Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer.
Rudnicka C, Mochizuki S, Okada Y, McLaughlin C, Leedman PJ, Stuart L, Epis M, Hoyne G, Boulos S, Johnson L, Schlaich M, Matthews V. Rudnicka C, et al. Medicine (Baltimore). 2016 Oct;95(40):e5085. doi: 10.1097/MD.0000000000005085. Medicine (Baltimore). 2016. PMID: 27749584 Free PMC article.
References
- J Pathol. 2005 Oct;207 (2):156-63 - PubMed
- J Cancer Res Clin Oncol. 2005 Jan;131(1):41-8 - PubMed
- Int J Oncol. 2005 Jan;26(1):17-24 - PubMed
- J Biol Chem. 2002 Dec 13;277(50):48210-9 - PubMed
- Int J Cancer. 2006 Jan 1;118(1):55-61 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical